Curis, Inc.
Every calculator, already run for CRIS
Open the full toolkit →You have the numbers on CRIS. Get the argument.
A written report on which of these readings actually decide the outcome for Curis, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
4 analysts covering CRISAnalyst Price Target Disagreement for Curis, Inc.
Wall Street's bull case implies +6400% from the current price; the bear case implies +1900%. A 4500% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CRIS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Curis, Inc.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-…
CRIS — frequently asked
Is CRIS a buy right now?
Wall Street's consensus rating on Curis, Inc. is none across 4 analysts, with a mean price target of $42.67 (+4167% vs. the current $1.00). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is CRIS overvalued?
CRIS trades at 0.3x trailing earnings. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is CRIS's next earnings date?
Curis, Inc. is next scheduled to report earnings around Nov 5, 2026. A full CRIS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Curis, Inc.?
Analysts covering Curis, Inc. (CRIS) range from a bear-case target of $20.00 to a bull-case high of $65.00, with a mean consensus target of $42.67 across 3 analysts. The spread of $45.00 (4500% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Curis, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Curis, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CRIS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Curis, Inc., in minutes. 3 free reports included with every account — no credit card required.